BOARD OF DIRECTORS
Craig Fraser joined Windtree in February of 2016 as President and Chief Executive Officer. He was also appointed to serve as a member of the Board of Directors in February 2016.
Mr. Fraser brings over 30 years of experience as a leader in both product development and commercial operations, and in building biopharmaceutical and device businesses for both startups and larger companies. Prior to joining Windtree, Mr. Fraser held executive positions at several biopharmaceutical companies, including as Chief Operating Officer at Novelion (AEGR) Pharmaceuticals, Vice
President of Global Disease Areas at Pfizer, Vice President and Global Business Manager at Wyeth, and Vice President of Sales & Marketing and Commercial Operations at Johnson & Johnson / Centocor. Mr. Fraser is a veteran of both the U.S. Marine Corps and the U.S. Army.
Mr. Fraser received his B.S. degree from Slippery Rock University of Pennsylvania.
Daniel E. Geffken
Daniel Geffken has served as a member of the Windtree Board of Directors since April 2019. He serves as Chairman of the Board’s Audit Committee and is a member of the Compensation Committee. Mr. Geffken brings more than 30 years of financial management experience to the board, ranging from start-ups to publicly traded companies with over $1 billion market capitalizations. Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has also served as Chief Financial Officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Directors of Elicio Bio, Alcobra Ltd., and Arcturus Inc., after its merger with Alcobra.
Mr. Geffken holds a BS from The Wharton School, University of Pennsylvania, and an M.B.A. from Harvard Business School.
DR. ROB SCOTT
Dr. Rob Scott has held leadership positions for over 30 years in the world’s leading biopharma companies, including J&J, Pfizer, Amgen, and AbbVie. During that time, he has led development teams responsible for highly successful brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq. Prior to his recent retirement as Chief Medical Officer and Head of Development for AbbVie, Dr. Scott was responsible for a team of over 4,000 individuals across 52 countries, a budget of nearly US$3 billion and programs involving more than 40 new molecular entities. Prior to joining AbbVie, Dr. Scott served as Vice President of Global Development for Amgen from 2010 and 2016, where he conducted, among other programs, heart failure development. From 2002 until 2007, he was the Chief Medical Officer and Executive Vice President of Research and Development at AtheroGenics. While there he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. Dr. Scott also worked for Pfizer, one of the world’s premier biopharmaceutical companies, from 1992 to 2002. While there, he was intimately involved in many cardiovascular clinical trials. He also was integral in developing the cholesterol drug Lipitor and Norvasc, a drug used to treat high blood pressure. Dr. Scott has served on many committees and boards, including as a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 until 2016, the board of Transcelerate, and as a member of the PhRMA Research and Development Leadership Forum.
Ms. Leslie Williams is a 25-year biopharmaceutical veteran and is an experienced biotech CEO and board of directors’ member. She has experience in healthcare, management, commercial product development and marketing. In 2010 she founded ImmusanT, Inc. and served as Director, President & CEO of ImmusanT until 2019. Prior to that she was President & CEO of Ventaira Pharmaceuticals and under her leadership the company became a significant player in the pulmonary drug-delivery market until it was sold at the end of 2007. Prior to Ventaira, Ms. Williams was director of marketing for INO Therapeutics, Inc. and additional experience includes commercial positions at Merck and GSK, and drug-delivery and -monitoring experience at Datex-Ohmeda (formerly Ohmeda, Inc.). She was a venture partner at Battelle Ventures where she sourced and evaluated deals and assisted early-stage technology companies with strategy, management, business development and M&A. She has served on several private, public, and non-profit boards. She is currently an operating partner at Accelerator Life Science Partners and serves on the Board of Ocular Therapeutix (OCUL) and on the Editorial Advisory Board of Life Science Leader. Ms. Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree with honors in nursing from the University of Iowa. Before entering industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa.